Relief Therapeutics announces supply deals with two companies for COVID-19 drug while awaiting trial data
30 September 2020 -

Swiss drug development company Relief Therapeutics (SWX:RLF) and its US partner, pharmaceutical company, NeuroRx, have struck deals with Bachem and Nephron Pharmaceuticals to supply and make a 50-year-old drug, aviptadil, Reuters news agency reported on Wednesday.

Reportedly, aviptadil is in clinical trials against COVID-19.

According to the companies, the deal with Swiss technology company Bachem, to supply peptides, and US generics maker Nephron, to manufacture aviptadil, also being called RLF-100 by the companies, is aimed at having supplies sufficient to treat one million patients, should the drug prove effective in the studies.